Hero

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting

1

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting

Celyad to Present Update to r/r AML and MDS Program at 2019 ASH Annual Meeting

2

Celyad to Present Update to r/r AML and MDS Program at 2019 ASH Annual Meeting

Celyad Highlights Abstracts from mCRC Clinical Program Released for SITC 34th Annual Meeting

3

Celyad Highlights Abstracts from mCRC Clinical Program Released for SITC 34th Annual Meeting

Celyad Announces October and November 2019 Investor Conference Schedule

4

Celyad Announces October and November 2019 Investor Conference Schedule

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Therapy for mCRC, from SITC 34th Annual Meeting

Celyad to Present Update to r/r AML and MDS Program at 2019 ASH Annual Meeting

Celyad to Present Update to r/r AML and MDS Program at 2019 ASH Annual Meeting

Celyad Highlights Abstracts from mCRC Clinical Program Released for SITC 34th Annual Meeting

Celyad Highlights Abstracts from mCRC Clinical Program Released for SITC 34th Annual Meeting

Discover all news

Carousel

Social Feed

In case you missed it: the webcast from our investor/analyst event is online: https://t.co/iWt4iXcIkZ @sitcancer $CYAD

12 hours ago

In case you missed it: the webcast from our investor/analyst event is online: https://t.co/iWt4iXcIkZ @sitcancer $CYAD

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Ther… https://t.co/zSTrdSf7wc

1 day ago

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Ther… https://t.co/zSTrdSf7wc

The event is webcast live: https://t.co/EUJz2IVadV #sitc2019 $CYAD https://t.co/JEkMeyr0QC

3 days ago

The event is webcast live: https://t.co/EUJz2IVadV #sitc2019 $CYAD https://t.co/JEkMeyr0QC

Celyad to Present Update to r/r AML and MDS Program at 2019 @ASH_hematology Annual Meeting $CYAD… https://t.co/ZuZKF5s1IR

6 days ago

Celyad to Present Update to r/r AML and MDS Program at 2019 @ASH_hematology Annual Meeting $CYAD… https://t.co/ZuZKF5s1IR

In case you missed it: the webcast from our investor/analyst event is online: https://t.co/iWt4iXcIkZ @sitcancer $CYAD

12 hours ago

In case you missed it: the webcast from our investor/analyst event is online: https://t.co/iWt4iXcIkZ @sitcancer $CYAD

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Ther… https://t.co/zSTrdSf7wc

1 day ago

Celyad Highlights Safety and Clinical Activity of CYAD-101, a First-In-Class, Non-Gene Edited Allogeneic CAR-T Ther… https://t.co/zSTrdSf7wc

The event is webcast live: https://t.co/EUJz2IVadV #sitc2019 $CYAD https://t.co/JEkMeyr0QC

3 days ago

The event is webcast live: https://t.co/EUJz2IVadV #sitc2019 $CYAD https://t.co/JEkMeyr0QC

Celyad to Present Update to r/r AML and MDS Program at 2019 @ASH_hematology Annual Meeting $CYAD… https://t.co/ZuZKF5s1IR

6 days ago

Celyad to Present Update to r/r AML and MDS Program at 2019 @ASH_hematology Annual Meeting $CYAD… https://t.co/ZuZKF5s1IR